2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Preamble 2072 1. Introduction 2074 2. Clinical Characteristics and Evaluation of AF 2076 3. Thromboembolic Risk and Treatment 2077 4. Rate Control: Recommendations 2079 5. Rhythm Control: Recommendations 2080 6. Specific Patient Groups and AF: Recommendations 2086 7. Evidence Gaps and Future Research Directions 2089 References 2090 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2095 Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 2097 Appendix 3. Initial Clinical Evaluation in Patients With AF 2104 The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized …

[1]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the Europe , 2011, Journal of the American College of Cardiology.

[2]  A. Laupacis,et al.  Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No Previous History of Stroke or Transient Ischemic Attacks , 2005, The Cochrane database of systematic reviews.

[3]  A. Forster,et al.  Effect of study setting on anticoagulation control: a systematic review and metaregression. , 2006, Chest.

[4]  G. Kay,et al.  Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis. , 2000, Circulation.

[5]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[6]  E. Aliot,et al.  Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. , 2007, The New England journal of medicine.

[7]  Tom Wong,et al.  A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. , 2013, Journal of the American College of Cardiology.

[8]  W. Evans,et al.  LONE AURICULAR FIBRILLATION , 1954, British heart journal.

[9]  M. Bulsara,et al.  The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). , 2003, Journal of the American College of Cardiology.

[10]  J. Jalife,et al.  Temporal Organization of Atrial Activity and Irregular Ventricular Rhythm During Spontaneous Atrial Fibrillation: , 2000, Journal of cardiovascular electrophysiology.

[11]  Salim Yusuf,et al.  Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial , 2011, Annals of Internal Medicine.

[12]  L. Tamariz,et al.  Pharmacological rate control of atrial fibrillation. , 2004, Cardiology clinics.

[13]  J. Halperin,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[14]  Dhanunjaya R. Lakkireddy,et al.  Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. , 2014, Journal of the American College of Cardiology.

[15]  Victor M Montori,et al.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. , 2011, Thyroid : official journal of the American Thyroid Association.

[16]  M. Brignole,et al.  Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. , 1998, Circulation.

[17]  P. Almgren,et al.  Genetic polymorphisms for estimating risk of atrial fibrillation in the general population: a prospective study. , 2012, Archives of internal medicine.

[18]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[19]  M. Brodsky,et al.  Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study , 2000, Circulation.

[20]  S. Ebrahim,et al.  Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation , 2001, BMJ : British Medical Journal.

[21]  Michel Haissaguerre,et al.  Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[22]  W. Rappel,et al.  Clinical Mapping Approach To Diagnose Electrical Rotors and Focal Impulse Sources for Human Atrial Fibrillation , 2012, Journal of cardiovascular electrophysiology.

[23]  J. Hirsh,et al.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[24]  Mark L. Greenberg,et al.  Precipitation of Ventricular Fibrillation by Intravenous Diltiazem and Metoprolol in a Young Patient with Occult Wolff‐Parkinson‐White Syndrome , 2008, Pacing and clinical electrophysiology : PACE.

[25]  Douglas W Mahoney,et al.  Left atrial volume as an index of left atrial size: a population-based study. , 2003, Journal of the American College of Cardiology.

[26]  P. Wolf,et al.  Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.

[27]  S. Themistoclakis,et al.  Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. , 2006, Heart rhythm.

[28]  M. Chung,et al.  Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. , 1998, Journal of the American College of Cardiology.

[29]  J. Cleland,et al.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? , 2003, Journal of the American College of Cardiology.

[30]  C. Negrão,et al.  Selective Atrial Vagal Denervation Guided by Evoked Vagal Reflex to Treat Patients With Paroxysmal Atrial Fibrillation , 2006, Circulation.

[31]  N. Boon,et al.  Thyroid disease and the heart , 2000, Heart.

[32]  V. Fuster,et al.  Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. , 1994, Circulation.

[33]  M. Ezekowitz,et al.  Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring , 1999, Journal of cardiovascular pharmacology and therapeutics.

[34]  M. Chang,et al.  Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. , 1995, European heart journal.

[35]  S. Johnston,et al.  Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States , 2011, Circulation. Cardiovascular quality and outcomes.

[36]  G. Lip,et al.  Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study , 2012, BMJ : British Medical Journal.

[37]  D. Packer,et al.  Long‐Term Outcome of Atrial Fibrillation Ablation: Impact and Predictors of Very Late Recurrence , 2010, Journal of cardiovascular electrophysiology.

[38]  Anticoagulants for Preventing Stroke in Patients With Nonrheumatic Atrial Fibrillation and a History of Stroke or Transient Ischemic Attack , 2004, The Cochrane database of systematic reviews.

[39]  D. Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .

[40]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[41]  Eric E. Smith,et al.  Variants conferring risk of atrial fibrillation on chromosome 4q25 , 2007, Nature.

[42]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[43]  Otto Kamp,et al.  Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. , 2004, Journal of the American College of Cardiology.

[44]  A. Zaman,et al.  Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. , 2004, American heart journal.

[45]  David O. Martin,et al.  Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation , 2013, Circulation. Arrhythmia and electrophysiology.

[46]  R. Damiano,et al.  The Cox maze IV procedure: predictors of late recurrence. , 2011, The Journal of thoracic and cardiovascular surgery.

[47]  S. Sack,et al.  Detection of atrial high-rate events by continuous Home Monitoring: clinical significance in the heart failure–cardiac resynchronization therapy population , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[48]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .

[49]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[50]  T. Petty,et al.  Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. , 1973, Chest.

[51]  R B D'Agostino,et al.  Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.

[52]  Clinical Efficacy of Amiodarone in the Treatment of Acute Myocardial Infarction Complicated by Atrial Fibrillation , 2012 .

[53]  T. Lehr,et al.  Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.

[54]  Affirm Investigators.  Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. , 2003, Journal of the American College of Cardiology.

[55]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Heart rhythm.

[56]  K. Ellenbogen,et al.  Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. , 1998, The American journal of cardiology.

[57]  J B Seward,et al.  Clinical profile and outcome of idiopathic restrictive cardiomyopathy. , 2000, Circulation.

[58]  K. Müller,et al.  Surgical treatment of atrial fibrillation using radiofrequency ablation , 2009 .

[59]  Stanley Nattel,et al.  Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications , 2008, Circulation. Arrhythmia and electrophysiology.

[60]  N. Smedira,et al.  Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[61]  N. Nikolaou,et al.  Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. , 2010, The American journal of cardiology.

[62]  Jesper Hastrup Svendsen,et al.  Familial Aggregation of Atrial Fibrillation: A Study in Danish Twins , 2009, Circulation. Arrhythmia and electrophysiology.

[63]  W. Ghali,et al.  Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. , 2011, Heart rhythm.

[64]  M. Kessentini,et al.  A Systematic Literature Review , 2016 .

[65]  Eric Boerwinkle,et al.  Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry , 2009, Nature Genetics.

[66]  I. Khan,et al.  Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. , 2003, International journal of cardiology.

[67]  J. Odell,et al.  Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.

[68]  M. Link,et al.  2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2012, Journal of the American College of Cardiology.

[69]  J. Bermejo,et al.  Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. , 2003, Journal of the American College of Cardiology.

[70]  P. Batin,et al.  A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. , 2004, European heart journal.

[71]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[72]  Ashok J. Shah,et al.  Teaching Rounds in Cardiac Electrophysiology How to Approach Reentrant Atrial Tachycardia After Atrial Fibrillation Ablation , 2012 .

[73]  D. Levy,et al.  Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.

[74]  E. Daoud,et al.  Left Ventricular‐Based Cardiac Stimulation Post AV Nodal Ablation Evaluation (The PAVE Study) , 2005, Journal of cardiovascular electrophysiology.

[75]  Laura A. Levit,et al.  Finding what works in health care : standards for systematic reviews , 2011 .

[76]  E. Kholmovski,et al.  Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. , 2011, Journal of the American College of Cardiology.

[77]  Jun Zhu,et al.  Efficacy and Safety of Apixaban in Patients Following Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE trial , 2013 .

[78]  M. Chung,et al.  Ascorbate Attenuates Atrial Pacing-Induced Peroxynitrite Formation and Electrical Remodeling and Decreases the Incidence of Postoperative Atrial Fibrillation , 2001, Circulation research.

[79]  Carlo Boffano,et al.  Radiofrequency Catheter Ablation of Atrial Fibrillation: A Cause of Silent Thromboembolism?: Magnetic Resonance Imaging Assessment of Cerebral Thromboembolism in Patients Undergoing Ablation of Atrial Fibrillation , 2010, Circulation.

[80]  Joshua J. E. Blauer,et al.  Detection and Quantification of Left Atrial Structural Remodeling With Delayed-Enhancement Magnetic Resonance Imaging in Patients With Atrial Fibrillation , 2009, Circulation.

[81]  Benjamin J. Epstein,et al.  Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure , 2007 .

[82]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. , 2012, Journal of the American College of Cardiology.

[83]  B. Gage,et al.  Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.

[84]  R. Califf,et al.  Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. , 2009, American heart journal.

[85]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[86]  E. E. van der Wall,et al.  Paroxysmal atrial fibrillation in male endurance athletes. A 9-year follow up. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[87]  S. Connolly,et al.  Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Lne Treatment of Symptomatic Atrial Fibrillation: (RAAFT 2): a Randomized Trial , 2012 .

[88]  Sanjiv M Narayan,et al.  Focal impulse and rotor modulation ablation of sustaining rotors abruptly terminates persistent atrial fibrillation to sinus rhythm with elimination on follow-up: a video case study. , 2012, Heart rhythm.

[89]  David O. Martin,et al.  Incidence of Atrial Fibrillation Post‐Cavotricuspid Isthmus Ablation in Patients with Typical Atrial Flutter: Left‐Atrial Size as an Independent Predictor of Atrial Fibrillation Recurrence , 2007, Journal of cardiovascular electrophysiology.

[90]  L. Lai,et al.  Left atrial dysfunction in patients with atrial fibrillation after successful rhythm control for > 3 months. , 2005, Chest.

[91]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[92]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[93]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[94]  N. Samani,et al.  Left atrial radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: a randomized controlled trial. , 2005, JAMA.

[95]  J. McMurray,et al.  Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. , 2012, Journal of the American College of Cardiology.

[96]  A. Capucci,et al.  Dronedarone for prevention of atrial fibrillation: a dose-ranging study. , 2003, European heart journal.

[97]  N. Takasu.  [Thyroid hormone and the cardiovascular system]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[98]  L. E. Peterson,et al.  Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. , 1988, European heart journal.

[99]  S. Owada,et al.  [Long-term efficacy of combination therapy using antiarrhythmic agents and angiotensin converting enzyme inhibitor in patients with paroxysmal and persistent atrial fibrillation: importance of the timing of administration]. , 2003, Journal of cardiology.

[100]  Ashok J. Shah,et al.  Localized reentry within the left atrial appendage: arrhythmogenic role in patients undergoing ablation of persistent atrial fibrillation. , 2011, Heart rhythm.

[101]  Mark A Hlatky,et al.  2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2013, Circulation.

[102]  R. Gianelly,et al.  Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome with atrial fibrillation. , 1985, Annals of emergency medicine.

[103]  L. Kalra,et al.  Are Cost Benefits of Anticoagulation for Stroke Prevention in Atrial Fibrillation Underestimated? , 2005, Stroke.

[104]  M. Josephson,et al.  Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. , 1999, The American journal of cardiology.

[105]  James B Seward,et al.  Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. , 2002, Journal of the American College of Cardiology.

[106]  J. Healey,et al.  A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation , 2009, Journal of cardiovascular electrophysiology.

[107]  C. Cannon,et al.  Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. , 2009, The American journal of cardiology.

[108]  R B D'Agostino,et al.  Secular trends in the prevalence of atrial fibrillation: The Framingham Study. , 1996, American heart journal.

[109]  D. Wyse,et al.  Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation , 2009, Journal of Interventional Cardiac Electrophysiology.

[110]  J A ABILDSKOV,et al.  Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. , 1959, American heart journal.

[111]  Wolters Kluwer,et al.  Hrs/ehra/ecas Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: a Report of the Heart Rhythm Society (hrs) Task Force , 2022 .

[112]  Albert Hofman,et al.  Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. , 2008, American heart journal.

[113]  B. Olshansky,et al.  Heart Failure and Sudden Death in Patients With Tachycardia-Induced Cardiomyopathy and Recurrent Tachycardia , 2004, Circulation.

[114]  W. Ghali,et al.  Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction. , 2010, The American journal of cardiology.

[115]  R. Hunter,et al.  Catheter Ablation of Atrial Fibrillation in Patients With Left Ventricular Systolic Dysfunction: A Systematic Review and Meta-Analysis , 2014, Circulation. Arrhythmia and electrophysiology.

[116]  Jagmeet P. Singh,et al.  Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. , 2008, Journal of the American College of Cardiology.

[117]  Burr Hall,et al.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. , 2010, JAMA.

[118]  C. M. Hart,et al.  Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. , 2002, Journal of the American College of Cardiology.

[119]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[120]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[121]  E. Aliot,et al.  Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[122]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[123]  Y. Adler,et al.  Colchicine Reduces Postoperative Atrial Fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) Atrial Fibrillation Substudy , 2011, Circulation.

[124]  M. Niebauer,et al.  Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. , 1994, The New England journal of medicine.

[125]  P. Alboni,et al.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. , 2004, The New England journal of medicine.

[126]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[127]  E. Lonn,et al.  Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. , 2005, American heart journal.

[128]  O. Ergene,et al.  Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study , 2004, Acta cardiologica.

[129]  C. Tondo,et al.  Atrial fibrillation: cure or treat? , 2009, Therapeutic advances in cardiovascular disease.

[130]  R. Cebul,et al.  Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. , 1995, American heart journal.

[131]  Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. , 2001, Journal of the American College of Cardiology.

[132]  P. Tchou,et al.  Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. , 2000, Circulation.

[133]  W. Hiatt,et al.  Proarrhythmic Potential of Dronedarone: Emerging Evidence from Spontaneous Adverse Event Reporting , 2012, Pharmacotherapy.

[134]  E. Michelson,et al.  Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. , 1989, The American journal of cardiology.

[135]  J. Epstein,et al.  Melanocyte‐like cells in the heart and pulmonary veins contribute to atrial arrhythmia triggers , 2009, The Journal of clinical investigation.

[136]  J. Dunning,et al.  Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[137]  A. Schaumann,et al.  Enhanced detection criteria in implantable cardioverter-defibrillators to avoid inappropriate therapy. , 1996, The American journal of cardiology.

[138]  Shien-Fong Lin,et al.  Intrinsic Cardiac Nerve Activity and Paroxysmal Atrial Tachyarrhythmia in Ambulatory Dogs , 2010, Circulation.

[139]  J. Lau,et al.  Systematic Review: Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation , 2009, Annals of Internal Medicine.

[140]  Dongfeng Qi,et al.  The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study , 2009, Circulation. Arrhythmia and electrophysiology.

[141]  D. Tamborero,et al.  Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[142]  J. Savino,et al.  Atrial fibrillation following coronary artery bypass graft surgery: Predictors, outcomes, and resource utilization , 1996 .

[143]  D. Benditt,et al.  Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. , 2010, Heart rhythm.

[144]  M. Scanavacca,et al.  Surgical treatment of atrial fibrillation through isolation of the left atrial posterior wall in patients with chronic rheumatic mitral valve disease. A randomized study with control group. , 2004, Arquivos brasileiros de cardiologia.

[145]  S. Nattel,et al.  The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. , 2012, European heart journal.

[146]  G. Wassmer,et al.  Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. , 2009, The Journal of thoracic and cardiovascular surgery.

[147]  M. Pfeffer,et al.  Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, American heart journal.

[148]  R. Leman.  Association Between Familial Atrial Fibrillation and Risk of New-Onset Atrial Fibrillation , 2011 .

[149]  J. Wodniecki,et al.  Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. , 1993, Cardiology.

[150]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[151]  M. Jensen-Urstad,et al.  factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation , 2001, Clinical cardiology.

[152]  Nancy M Albert,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, The Journal of thoracic and cardiovascular surgery.

[153]  [A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation]. , 1992, La Clinica terapeutica.

[154]  B. Lindsay,et al.  Noninvasive Characterization of Epicardial Activation in Humans With Diverse Atrial Fibrillation Patterns , 2010, Circulation.

[155]  J. Ruskin,et al.  Familial aggregation in lone atrial fibrillation , 2005, Human Genetics.

[156]  Neural mechanisms of atrial fibrillation , 2012, Current opinion in cardiology.

[157]  W. Dassen,et al.  A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. , 1984, Circulation.

[158]  S. Narayan,et al.  Five-year outcomes after segmental pulmonary vein isolation for paroxysmal atrial fibrillation. , 2009, The American journal of cardiology.

[159]  J. Ruskin,et al.  Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. , 2013, Journal of the American College of Cardiology.

[160]  Bramahn . Singh,et al.  Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. , 1999, Journal of the American College of Cardiology.

[161]  F. Morady,et al.  Characteristics of Cavotricuspid Isthmus–Dependent Atrial Flutter After Left Atrial Ablation of Atrial Fibrillation , 2006, Circulation.

[162]  T. Agner,et al.  A reevaluation of atrial fibrillation in thyrotoxicosis. , 1984, Danish medical bulletin.

[163]  B. Gersh,et al.  Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[164]  G. Lip,et al.  Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation , 2012, Circulation.

[165]  D. Singer,et al.  Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. , 2012, The American journal of cardiology.

[166]  E. Aliot,et al.  Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[167]  M. Allessie,et al.  Electrical, contractile and structural remodeling during atrial fibrillation. , 2002, Cardiovascular research.

[168]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[169]  J. Belmin,et al.  Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. , 2015, The Cochrane database of systematic reviews.

[170]  J. Ramires,et al.  Effectiveness of the Maze Procedure Using Cooled-Tip Radiofrequency Ablation in Patients With Permanent Atrial Fibrillation and Rheumatic Mitral Valve Disease , 2005, Circulation.

[171]  P. Sanders,et al.  Electrophysiologic and electroanatomic changes in the human atrium associated with age. , 2004, Journal of the American College of Cardiology.

[172]  V. Hasselblad,et al.  Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. , 2009, Journal of the American College of Cardiology.

[173]  A. Raviele,et al.  Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation A Meta-Analysis of Randomized Controlled Trials. , 2008, Journal of atrial fibrillation.

[174]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[175]  C. Good,et al.  Amiodarone to prevent recurrence of atrial fibrillation. , 2000, The New England journal of medicine.

[176]  J. Healey,et al.  Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. , 2013, The Cochrane database of systematic reviews.

[177]  J. Williams,et al.  Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. , 1999, The American journal of cardiology.

[178]  René M. Botnar,et al.  Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. , 2007, Radiology.

[179]  D. Levy,et al.  Pulse pressure and risk of new-onset atrial fibrillation. , 2007, JAMA.

[180]  Paul J. Pearson,et al.  Left atrial appendage occlusion: lessons learned from surgical and transcatheter experiences. , 2011, The Annals of thoracic surgery.

[181]  V. Chair,et al.  ACCF/AHA Practice Guideline 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011 .

[182]  J. McMurray,et al.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.

[183]  J. Steinberg,et al.  Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. , 1987, Journal of the American College of Cardiology.

[184]  J. Langberg,et al.  Atrial Fibrillation Increases Production of Superoxide by the Left Atrium and Left Atrial Appendage: Role of the NADPH and Xanthine Oxidases , 2005, Circulation.

[185]  G. Wassmer,et al.  Preoperative statin therapy for patients undergoing cardiac surgery. , 2012, The Cochrane database of systematic reviews.

[186]  E. Heist,et al.  Analysis of the left atrial appendage by magnetic resonance angiography in patients with atrial fibrillation. , 2006, Heart rhythm.

[187]  P. Vestergaard,et al.  Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. , 2005, The American journal of medicine.

[188]  J Haaksma,et al.  Analysis of vagal effects on ventricular rhythm in patients with atrial fibrillation. , 1994, Clinical science.

[189]  Habib Gamra,et al.  Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry , 2012, Circulation. Arrhythmia and electrophysiology.

[190]  P. Kirchhof,et al.  Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. , 2010, Basic & clinical pharmacology & toxicology.

[191]  R. Campbell,et al.  Antiarrhythmic drugs , 1995, Springer Berlin Heidelberg.

[192]  Frederick T. Han,et al.  Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. , 2013, Journal of the American College of Cardiology.

[193]  B. Phillips,et al.  Comparison of Intravenous Diltiazem and Verapamil for the Acute Treatment of Atrial Fibrillation and Atrial Flutter , 1997, Pharmacotherapy.

[194]  P. Neužil,et al.  Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial , 2013, Circulation.

[195]  I. Khan.  Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. , 2001, Journal of the American College of Cardiology.

[196]  S Nattel,et al.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. , 1999, Circulation.

[197]  Hugh Calkins,et al.  Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. , 2011, Heart rhythm.

[198]  J. Stockigt,et al.  Atrial fibrillation and arterial embolism in hyperthyroidism. , 1981, Australian and New Zealand journal of medicine.

[199]  J. Ruskin,et al.  Clinical Subtypes of Lone Atrial Fibrillation , 2005, Pacing and clinical electrophysiology : PACE.

[200]  Matthew R. Reynolds,et al.  Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency Ablation: Two Systematic Literature Reviews and Meta-Analyses , 2009, Circulation. Arrhythmia and electrophysiology.

[201]  J. Mounsey,et al.  Antiarrhythmic drug therapy of atrial fibrillation. , 2004, Cardiology clinics.

[202]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[203]  J Jalife,et al.  Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. , 2000, Circulation.

[204]  H. Halperin,et al.  Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. , 2011, Heart rhythm.

[205]  Jacky Serveille,et al.  [Ablation of atrial fibrillation]. , 2008, Soins; la revue de reference infirmiere.

[206]  P. Loewen,et al.  Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules , 2011, Annals of Hematology.

[207]  M. Mack,et al.  Minimally invasive surgical ablation of atrial fibrillation: six-month results. , 2009, The Journal of thoracic and cardiovascular surgery.

[208]  G. Boriani,et al.  Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. , 2011, Journal of the American College of Cardiology.

[209]  P. Vardas,et al.  Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. , 2005, European heart journal.

[210]  L. Popescu,et al.  Interstitial Cajal-like cells (ICLC) in myocardial sleeves of human pulmonary veins , 2008, Journal of cellular and molecular medicine.

[211]  Elia Biganzoli,et al.  Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.

[212]  J. Molnar,et al.  Prevention of Atrial Fibrillation by Way of Abrogation of the Renin-Angiotensin System: A Systematic Review and Meta-Analysis , 2008, American journal of therapeutics.

[213]  J. Davy,et al.  Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. , 2008, American heart journal.

[214]  Bruce M Psaty,et al.  Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.

[215]  S. Lévy,et al.  [Oral propranolol in Wolff-Parkinson-White syndrome. Electrophysiological data]. , 1991, Archives des maladies du coeur et des vaisseaux.

[216]  M. Nebojša,et al.  Lethal Outcome After Intravenous Administration of Amiodarone in Patient with Atrial Fibrillation and Ventricular Preexcitation , 2011, Journal of cardiovascular electrophysiology.

[217]  J. Hirsh,et al.  Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. , 2014, Future cardiology.

[218]  J. Gaddum,et al.  The Pharmacological Basis of Therapeutics , 1966 .

[219]  Robert F Kushner,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[220]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[221]  David O. Martin,et al.  Atrial Fibrillation Ablation in Patients With Therapeutic International Normalized Ratio: Comparison of Strategies of Anticoagulation Management in the Periprocedural Period , 2007, Circulation.

[222]  M. Pfeffer,et al.  Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, American heart journal.

[223]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.

[224]  S. Hariharan,et al.  Clinical Pharmacology Basis of Deriving Dosing Recommendations for Dabigatran in Patients With Severe Renal Impairment , 2012, Journal of clinical pharmacology.

[225]  S. Nattel,et al.  Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[226]  H. Pak,et al.  Safety and Convenience of Continuous Warfarin Strategy During the Periprocedural Period in Patients Who Underwent Catheter Ablation of Atrial Fibrillation , 2009, Journal of cardiovascular electrophysiology.

[227]  Atul Verma,et al.  Pacemaker or defibrillator surgery without interruption of anticoagulation. , 2013, The New England journal of medicine.

[228]  E. Aliot,et al.  Rationale and current perspective for early rhythm control therapy in atrial fibrillation , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[229]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[230]  J. Boineau,et al.  Atrial Tachyarrhythmias After the Maze Procedure: Incidence and Prognosis , 2004, Circulation.

[231]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[232]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[233]  S. Mittal,et al.  Ganglionated plexus ablation vs linear ablation in patients undergoing pulmonary vein isolation for persistent/long-standing persistent atrial fibrillation: a randomized comparison. , 2013, Heart rhythm.

[234]  I. Savelieva,et al.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[235]  M. Aguilar,et al.  Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. , 2005, The Cochrane database of systematic reviews.

[236]  Richard A. Kronmal,et al.  N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation: The Cardiovascular Health Study , 2009, Circulation.

[237]  Stefan Kääb,et al.  Genetics of Atrial Fibrillation: Implications for Future Research Directions and Personalized Medicine , 2010, Circulation. Arrhythmia and electrophysiology.

[238]  Jun Zhu,et al.  Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.

[239]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[240]  S. Yusuf,et al.  Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial , 2010, The Lancet Neurology.

[241]  G. Lip,et al.  Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. , 2013, European heart journal.

[242]  Sean M. O'Brien,et al.  Surgical ablation of atrial fibrillation trends and outcomes in North America. , 2012, The Journal of thoracic and cardiovascular surgery.

[243]  N. Georgiev.  [Multifocal atrial tachycardia]. , 2020, Vutreshni bolesti.

[244]  A. Capucci,et al.  Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. , 1996, American heart journal.

[245]  T. Arentz,et al.  Microparticles in atrial fibrillation: a link between cell activation or apoptosis, tissue remodelling and thrombogenicity. , 2013, International journal of cardiology.

[246]  D. Scherf,et al.  Experimental studies on auricular flutter and auricular fibrillation. , 1948, American heart journal.

[247]  Sunil K. Agarwal,et al.  Absolute and Attributable Risks of Atrial Fibrillation in Relation to Optimal and Borderline Risk Factors: The Atherosclerosis Risk in Communities (ARIC) Study , 2011, Circulation.

[248]  A. Waldo.  Reversal of Left Ventricular Dysfunction Following Ablation of Atrial Fibrillation , 2008 .

[249]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[250]  K. Lunetta,et al.  Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. , 2014, Journal of the American College of Cardiology.

[251]  G. Klein,et al.  Acceleration of the Ventricular Response During Atrial Fibrillation in the Wolff‐Parkinson‐White Syndrome After Verapamil , 1982, Circulation.

[252]  J. Prutkin,et al.  Catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy , 2016, Heart.

[253]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[254]  S. Yusuf,et al.  Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.

[255]  J Clémenty,et al.  A focal source of atrial fibrillation treated by discrete radiofrequency ablation. , 1997, Circulation.

[256]  S. Mohiuddin,et al.  Pharmacological Management of Atrial Fibrillation following Cardiac Surgery , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[257]  I. V. Van Gelder,et al.  Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. , 1989, The American journal of cardiology.

[258]  M. Haumer,et al.  Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias , 2001, Critical care medicine.

[259]  José Antônio Valle Antunes,et al.  Systematic Literature Review , 2021, Literature Reviews.

[260]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study , 2006, Circulation.

[261]  M. Pfeffer,et al.  Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. , 2006, American heart journal.

[262]  J. Mathew,et al.  A multicenter risk index for atrial fibrillation after cardiac surgery. , 2004, JAMA.

[263]  S. Yusuf,et al.  Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. , 2004, The Cochrane database of systematic reviews.

[264]  K. Hashiba,et al.  Prediction of a fatal atrial fibrillation in patients with asymptomatic Wolff-Parkinson-White pattern. , 1990, Japanese circulation journal.

[265]  F. Morady,et al.  A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. , 2000, Journal of the American College of Cardiology.

[266]  D. Hilleman,et al.  Pharmacologic Prophylaxis of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Beyond β‐Blockers , 2010, Pharmacotherapy.

[267]  U. Goldbourt,et al.  Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction , 1992 .

[268]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[269]  A. Zbrozek,et al.  Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. , 1993, The American journal of cardiology.

[270]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[271]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[272]  M. Josephson,et al.  Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.

[273]  A L Waldo,et al.  Characterization of Atrial Flutter: Studies in Man After Open Heart Surgery Using Fixed Atrial Electrodes , 1979, Circulation.

[274]  M. Monreal,et al.  Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.

[275]  Liming Zhang,et al.  Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties , 2003, The Journal of physiology.

[276]  M. Niemelä,et al.  Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. , 2007, European heart journal.

[277]  O. Alfieri,et al.  Pulmonary Vein Denervation Enhances Long-Term Benefit After Circumferential Ablation for Paroxysmal Atrial Fibrillation , 2004, Circulation.

[278]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[279]  M. Gold.  Effect of Home Testing of International Normalized Ratio on Clinical Events , 2011 .

[280]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[281]  R. Steinman,et al.  Amiodarone-induced torsade de pointes in a patient with wolff-Parkinson-White syndrome. , 2009, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[282]  Pablo A. Chiale,et al.  Efficacy of Amiodarone for the Termination of Chronic Atrial Fibrillation and Maintenance of Normal Sinus Rhythm: A Prospective, Multicenter, Randomized, Controlled, Double Blind Trial , 2001, Journal of cardiovascular pharmacology and therapeutics.

[283]  Prashanthan Sanders,et al.  Catheter ablation for atrial fibrillation in congestive heart failure. , 2004, The New England journal of medicine.

[284]  M. Link,et al.  2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2012, The Journal of thoracic and cardiovascular surgery.

[285]  Philippe Pibarot,et al.  Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. , 2008, Journal of the American College of Cardiology.

[286]  G. Hindricks,et al.  ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[287]  X. Jouven,et al.  Atrial Fibrillation and Death After Myocardial Infarction: A Community Study , 2011, Circulation.

[288]  G. Lamas,et al.  Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict Death and Stroke: Report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST) , 2003, Circulation.

[289]  David M Herrington,et al.  C-Reactive Protein, Carotid Intima-Media Thickness, and Incidence of Ischemic Stroke in the Elderly: The Cardiovascular Health Study , 2003, Circulation.

[290]  Janet S. Wright,et al.  2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi , 2011, Journal of the American College of Cardiology.

[291]  Albert L. Waldo,et al.  Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications. , 2008, Journal of the American College of Cardiology.

[292]  M. Keltai,et al.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2012, European heart journal.

[293]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[294]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[295]  D. Mozaffarian,et al.  Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. , 2012, JAMA.

[296]  P. Schweitzer,et al.  Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. , 1998, The American journal of cardiology.

[297]  R Slama,et al.  [The atrial arrhythmia syndrome of vagal origin]. , 1978, Archives des maladies du coeur et des vaisseaux.

[298]  B. Maron,et al.  Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. , 1979, Circulation.

[299]  K. Lunetta,et al.  Meta-analysis identifies six new susceptibility loci for atrial fibrillation , 2012, Nature Genetics.

[300]  Judith S. Hochman,et al.  2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[301]  S. Lévy,et al.  Predictors of In‐Hospital Mortality After DC Catheter Ablation of Atrioventricular Junction: Results of a Prospective, International, Multicenter Study , 1991, Circulation.

[302]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[303]  H. Crijns,et al.  Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. , 1993, The American journal of cardiology.

[304]  G. Breithardt,et al.  Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial Running title: Goette et al.; The ANTIPAF Trial , 2010 .

[305]  J. McMurray,et al.  Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. , 1989, Journal of cardiovascular pharmacology.

[306]  M. Russo,et al.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.

[307]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[308]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[309]  池田 達則.  Augmented single-unit muscle sympathetic nerve activity in heart failure with chronic atrial fibrillation , 2012 .

[310]  T. Sundt,et al.  Correction: 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Journal of the American College of Cardiology (2014) 63 (2438-88)) , 2014 .

[311]  Christopher Piorkowski,et al.  Perception of Atrial Fibrillation Before and After Radiofrequency Catheter Ablation: Relevance of Asymptomatic Arrhythmia Recurrence , 2005, Circulation.

[312]  R. Page,et al.  Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. , 2003, The American journal of cardiology.

[313]  Stanley Nattel,et al.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.

[314]  Donald R. Lynch.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[315]  G. Lip,et al.  Atrial fibrillation , 2012, The Lancet.

[316]  J. Brugada,et al.  Ventricular Fibrillation and Sudden Death After Radiofrequency Catheter Ablation of the Atrioventricular Junction , 1997, Pacing and clinical electrophysiology : PACE.

[317]  M. Franzosi,et al.  Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. , 2010, American heart journal.

[318]  D. Lake,et al.  Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. , 2012, The American journal of medicine.

[319]  Tong Liu,et al.  Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. , 2008, International journal of cardiology.

[320]  P. Petersen.  Thromboembolic complications in atrial fibrillation. , 1990, Stroke.

[321]  S. Redline,et al.  Role of obstructive sleep apnea in cardiovascular disease , 2011, Current opinion in cardiology.

[322]  J Clémenty,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[323]  J. Vandenbroucke,et al.  Optimal oral anticoagulant therapy in patients with mechanical heart valves. , 1995, The New England journal of medicine.

[324]  Nick Freemantle,et al.  Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[325]  P. Vestergaard,et al.  Work related physical activity and risk of a hospital discharge diagnosis of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study , 2004, Occupational and Environmental Medicine.

[326]  E. Blackstone,et al.  Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. , 2008, Journal of the American College of Cardiology.

[327]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[328]  A. Camm,et al.  Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[329]  G. Hasenfuss,et al.  CaMKII-Dependent Diastolic SR Ca2+ Leak and Elevated Diastolic Ca2+ Levels in Right Atrial Myocardium of Patients With Atrial Fibrillation , 2010, Circulation research.

[330]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.

[331]  G. Guyatt,et al.  Practice guidelines , 1996, Journal of General Internal Medicine.

[332]  P. Petersen,et al.  Stroke in thyrotoxicosis with atrial fibrillation. , 1988, Stroke.

[333]  Gregory Y H Lip,et al.  New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation , 2012, Expert review of cardiovascular therapy.

[334]  Petr Neuzil,et al.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.

[335]  D. Lin,et al.  Efficacy and Risk of Atrial Fibrillation Ablation Before 45 Years of Age , 2010, Circulation. Arrhythmia and electrophysiology.

[336]  M. Fishbein,et al.  Neural mechanisms of atrial arrhythmias , 2012, Nature Reviews Cardiology.

[337]  L. Køber,et al.  Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy , 2001, Circulation.

[338]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[339]  Ralph B D'Agostino,et al.  Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. , 2004, JAMA.

[340]  M. Hirai,et al.  Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[341]  Lluís Mont,et al.  Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study) , 2013, European heart journal.

[342]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[343]  Nancy M Albert,et al.  2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[344]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.

[345]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[346]  D. Holmes,et al.  Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. , 2009, Journal of the American College of Cardiology.

[347]  E. Benjamin,et al.  Outcomes of Medicare Beneficiaries Undergoing Catheter Ablation for Atrial Fibrillation , 2012, Circulation.

[348]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[349]  K. Koh,et al.  Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. , 1995, The American journal of cardiology.

[350]  A. Waldo.  Radiofrequency Ablation vs Antiarrhythmic Drugs as First-line Treatment of Symptomatic Atrial Fibrillation: A Randomized Trial , 2006 .

[351]  D. Packer,et al.  Success of Ablation for Atrial Fibrillation in Isolated Left Ventricular Diastolic Dysfunction: A Comparison to Systolic Dysfunction and Normal Ventricular Function , 2011, Circulation. Arrhythmia and electrophysiology.

[352]  M. Akhtar,et al.  Effect of Lidocaine on Atrioventricular Response Via the Accessory Pathway in Patients with Wolff‐Parkinson‐White Syndrome , 1981, Circulation.

[353]  Kenneth A. Ellenbogen,et al.  The Ablate and Pace Trial: A Prospective Study of Catheter Ablation of the AV Conduction System and Permanent Pacemaker Implantation for Treatment of Atrial Fibrillation , 2004, Journal of Interventional Cardiac Electrophysiology.

[354]  Brian Olshansky,et al.  The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[355]  D. Lambrechts,et al.  The Association of the 4q25 Susceptibility Variant for Atrial Fibrillation With Stroke Is Limited to Stroke of Cardioembolic Etiology , 2010, Stroke.

[356]  U. Ozbek,et al.  Combined radiofrequency modified maze and mitral valve procedure through a port access approach: early and mid-term results. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[357]  Catherine Klersy,et al.  Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. , 2006, Journal of the American College of Cardiology.

[358]  Robby Nieuwlaat,et al.  Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. , 2010, Journal of the American College of Cardiology.

[359]  M. Rienstra,et al.  An Update on the Prognosis of Patients With Atrial Fibrillation , 2012, Circulation.

[360]  M. Kinoshita,et al.  Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. , 1997, Japanese circulation journal.

[361]  R. Becker,et al.  Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. , 2005, Journal of the American College of Cardiology.

[362]  Thomas E. Moritz,et al.  Atrial fibrillation after cardiac surgery: a major morbid event? , 1997, Annals of surgery.

[363]  G. Steinbeck,et al.  Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. , 2000, European heart journal.

[364]  T. Wieland,et al.  Enhanced Sarcoplasmic Reticulum Ca2+ Leak and Increased Na+-Ca2+ Exchanger Function Underlie Delayed Afterdepolarizations in Patients With Chronic Atrial Fibrillation , 2012, Circulation.

[365]  Janusz Wnek,et al.  2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[366]  R. Winkle,et al.  The Use of Dabigatran Immediately After Atrial Fibrillation Ablation , 2012, Journal of cardiovascular electrophysiology.

[367]  J. Alpert,et al.  Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. , 1990, American heart journal.

[368]  F. Morady,et al.  Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery , 1997 .

[369]  Christopher E Hilker,et al.  Incidence of Newly Detected Atrial Arrhythmias via Implantable Devices in Patients With a History of Thromboembolic Events , 2010, Stroke.

[370]  M. Josephson,et al.  Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. , 2003, The American journal of cardiology.

[371]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[372]  Bernhard Meier,et al.  Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[373]  G. Kay,et al.  Proarrhythmic Aspects of Atrial Fibrillation Surgery: Mechanisms of Postoperative Macroreentrant Tachycardias , 2008, Circulation.

[374]  W. Baker,et al.  Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.

[375]  N. V. van Hemel,et al.  A randomized study of combining maze surgery for atrial fibrillation with mitral valve surgery. , 2003, The Journal of cardiovascular surgery.

[376]  R. Hart,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 2000 .

[377]  M. Brignole,et al.  Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. , 1997, Circulation.

[378]  R. Bergemann,et al.  Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. , 2005, Chest.

[379]  Nancy R Cook,et al.  Relation of vigorous exercise to risk of atrial fibrillation. , 2009, The American journal of cardiology.

[380]  M. Coceani,et al.  Catheter Ablation of Long‐Lasting Persistent Atrial Fibrillation: Clinical Outcome and Mechanisms of Subsequent Arrhythmias , 2006, Journal of cardiovascular electrophysiology.

[381]  苅尾 七臣,et al.  ガイドライン解説 AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease : 2011 update , 2012 .

[382]  J. Olesen,et al.  The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study , 2012, Thrombosis and Haemostasis.

[383]  G. Breithardt,et al.  The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[384]  N. Kanuru,et al.  Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. , 2002, Journal of the American College of Cardiology.

[385]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[386]  W. Shen,et al.  Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. , 2013, Heart rhythm.

[387]  P. Zimetbaum,et al.  Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? , 2010, The American journal of medicine.

[388]  J Abrams,et al.  Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. , 1985, American heart journal.

[389]  J. Halperin,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[390]  N. Limdi,et al.  Kidney function influences warfarin responsiveness and hemorrhagic complications. , 2009, Journal of the American Society of Nephrology : JASN.

[391]  C. Polanczyk,et al.  Very Low Risk of Thromboembolic Events in Patients Undergoing Successful Catheter Ablation of Atrial Fibrillation With a CHADS2 Score ⩽3: A Long-Term Outcome Study , 2011, Circulation. Arrhythmia and electrophysiology.

[392]  C. Steinwender,et al.  Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. , 2006, International journal of cardiology.

[393]  K. Furie,et al.  Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. , 2012, Stroke.

[394]  K. Ellenbogen,et al.  Long-Term Outcomes After Catheter Ablation of Cavo-Tricuspid Isthmus Dependent Atrial Flutter: A Meta-Analysis , 2009, Circulation. Arrhythmia and electrophysiology.

[395]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[396]  J. Brugada,et al.  Long-lasting sport practice and lone atrial fibrillation. , 2002, European heart journal.

[397]  J. Halperin,et al.  Prevention of stroke in patients with atrial fibrillation , 2012, Journal of Interventional Cardiac Electrophysiology.

[398]  Niels Voigt,et al.  Recent advances in the molecular pathophysiology of atrial fibrillation. , 2011, The Journal of clinical investigation.

[399]  Talicia Tarver,et al.  HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION , 2014 .

[400]  G F Michaud,et al.  Electrocardiographic differentiation of atrial flutter from atrial fibrillation by physicians. , 1999, Journal of electrocardiology.

[401]  J. Boineau,et al.  The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. , 2003, The Journal of thoracic and cardiovascular surgery.

[402]  N. Peters,et al.  Can atrial fibrillation with a coarse electrocardiographic appearance be treated with catheter ablation of the tricuspid valve–inferior vena cava isthmus? Results of a multicentre randomised controlled trial , 2006, Heart.

[403]  Fredrik Folke,et al.  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.

[404]  P. Vestergaard,et al.  Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. , 2004, Archives of internal medicine.

[405]  G. Hindricks,et al.  Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[406]  A. Camm,et al.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[407]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[408]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[409]  F. Morady,et al.  Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. , 1998, The New England journal of medicine.

[410]  C. Lau,et al.  Comparison Of Digoxin Versus Low‐Dose Amiodarone For Ventricular Rate Control In Patients With Chronic Atrial Fibrillation , 2001, Clinical and experimental pharmacology & physiology.

[411]  A. Camm,et al.  Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[412]  S. Steinhubl,et al.  Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. , 2004, American heart journal.

[413]  J. Thomas,et al.  Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. , 2000, American heart journal.

[414]  Wen-Chung Yu,et al.  Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. , 2003, European heart journal.

[415]  D. V. Van Wagoner,et al.  Prednisone Prevents Inducible Atrial Flutter in the Canine Sterile Pericarditis Model , 2007, Journal of cardiovascular electrophysiology.

[416]  P. Vardas,et al.  Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. , 2001, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[417]  Elsayed Z Soliman,et al.  Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. , 2009, American heart journal.

[418]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[419]  A. Waldo.  Substrate and Procedural Predictors of Outcomes After Catheter Ablation for Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy , 2009 .

[420]  B. Maron,et al.  Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[421]  S. Themistoclakis,et al.  The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. , 2010, Journal of the American College of Cardiology.

[422]  M. Böhm,et al.  Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition , 2010 .

[423]  C. Morillo,et al.  Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. , 2013, JAMA internal medicine.

[424]  Harlan M Krumholz,et al.  Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.

[425]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[426]  T. Guarnieri,et al.  Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. , 1999, Journal of the American College of Cardiology.

[427]  F. Morady,et al.  Risk of Thromboembolic Events After Percutaneous Left Atrial Radiofrequency Ablation of Atrial Fibrillation , 2006, Circulation.

[428]  S. Connolly,et al.  A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). , 2012, American heart journal.

[429]  M. Leoncini,et al.  Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. , 2001, The American journal of cardiology.

[430]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[431]  O. Centurión.  Atrial Fibrillation in the Wolff-Parkinson-White Syndrome. , 2011, Journal of atrial fibrillation.

[432]  Joshua J. E. Blauer,et al.  New magnetic resonance imaging based method to define extent of left atrial wall injury after the ablation of atrial fibrillation , 2008 .

[433]  D. Goff,et al.  Erratum: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (J Am Coll Cardiol (2013) DOI:10.1016/j.jacc.2013.11.005) , 2014 .

[434]  Stephan Willems,et al.  Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. , 2009, European heart journal.

[435]  K. Chandrasekaran,et al.  Safety of expedited anticoagulation in patients undergoing transesophageal echocardiographic-guided cardioversion. , 2006, The American journal of medicine.

[436]  S. Goldstein,et al.  Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. , 1988, Chest.

[437]  M. Domanski,et al.  Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study , 2004, Circulation.

[438]  F. Morady,et al.  Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. , 2013, Heart rhythm.

[439]  H. I. Çikriklar,et al.  Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation , 2005, Emergency Medicine Journal.

[440]  H. May,et al.  Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. , 2013, Heart rhythm.

[441]  Y. Ohashi,et al.  Alcohol consumption and risk of atrial fibrillation: a meta-analysis. , 2011, Journal of the American College of Cardiology.

[442]  B. Winters,et al.  &ggr;‐Adrenergic Blockade Accelerates Conversion of Postoperative Supraventricular Tachyarrhythmias , 1998, Anesthesiology.

[443]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[444]  J. Halperin,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[445]  J. Le Heuzey,et al.  A Short‐Term, Randomized, Double‐Blind, Parallel‐Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study , 2010, Journal of cardiovascular electrophysiology.

[446]  Hugh Calkins,et al.  Characterization of radiofrequency ablation lesions with gadolinium-enhanced cardiovascular magnetic resonance imaging. , 2006, Journal of the American College of Cardiology.

[447]  G. Lip,et al.  Underuse of oral anticoagulants in atrial fibrillation: a systematic review. , 2010, The American journal of medicine.

[448]  Frank Bogun,et al.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation. , 2006, The New England journal of medicine.

[449]  Marsha E Reichman,et al.  Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.

[450]  F. Gaita,et al.  Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. , 2007, The American journal of cardiology.

[451]  G. Kay,et al.  Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. , 1997, Journal of the American College of Cardiology.

[452]  Nassir Marrouche,et al.  Atrial Fibrosis Quantified Using Late Gadolinium Enhancement MRI is Associated With Sinus Node Dysfunction Requiring Pacemaker Implant , 2012, Journal of cardiovascular electrophysiology.

[453]  J. Lau,et al.  Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation , 2009 .

[454]  Silvia G Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.

[455]  M. Rosenqvist,et al.  Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. , 2007, European heart journal.

[456]  David O. Martin,et al.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. , 2008, The New England journal of medicine.

[457]  V. Menon,et al.  Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. , 2012, Archives of internal medicine.

[458]  Gerhard Hindricks,et al.  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. , 2012, The New England journal of medicine.

[459]  J. Macgregor,et al.  The effects of rate and irregularity on sympathetic nerve activity in human subjects. , 2007, Heart rhythm.

[460]  Eric Boerwinkle,et al.  Independent Susceptibility Markers for Atrial Fibrillation on Chromosome 4q25 , 2010, Circulation.

[461]  L. Schamroth.  Immediate effects of intravenous verapamil on atrial fibrillation. , 1971, Cardiovascular research.

[462]  R. D'Agostino,et al.  Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. , 1994, The New England journal of medicine.

[463]  S. Mouly,et al.  Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. , 2006, Archives of internal medicine.

[464]  P. Kowey,et al.  Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. , 1999, Circulation.

[465]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. , 2003, The American journal of cardiology.

[466]  N. Varma,et al.  Surface Electrocardiographic Patterns and Electrophysiologic Characteristics of Atrial Flutter Following Modified Radiofrequency MAZE Procedures , 2007, Journal of cardiovascular electrophysiology.

[467]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[468]  Helmut Baumgartner,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[469]  D. Atar,et al.  Dronedarone in high-risk permanent atrial fibrillation. , 2011, The New England journal of medicine.

[470]  P. Kirchhof,et al.  Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. , 2009, Journal of the American College of Cardiology.

[471]  J. Hartikainen,et al.  The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial: clinical rationale, study design, and implementation. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[472]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[473]  P. Thompson,et al.  EMBOLISM IN THYROTOXIC ATRIAL FIBRILLATION , 1979, The Medical journal of Australia.

[474]  L. La Vecchia,et al.  Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials , 2010, Journal of cardiovascular medicine.

[475]  Νικόλαος Μπαϊκούσης,et al.  Pharmacologic prophylaxis for atrial fibrillation following cardiac surgery: a systematic review , 2010 .

[476]  G. Breithardt,et al.  Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial , 2012, The Lancet.

[477]  Paul J. Wang,et al.  Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[478]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[479]  M. Rosen,et al.  Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation , 2005, Circulation.

[480]  B. Iung,et al.  AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. , 1996, Circulation.

[481]  Silvia G Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.

[482]  Kathleen F. Kerr,et al.  European Ancestry as a Risk Factor for Atrial Fibrillation in African Americans , 2010, Circulation.

[483]  Michael J Pencina,et al.  Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. , 2010, JAMA.

[484]  Otto Kamp,et al.  Lenient versus strict rate control in patients with atrial fibrillation. , 2010, The New England journal of medicine.

[485]  F. Morady,et al.  Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. , 1999, The New England journal of medicine.

[486]  D. Fernández de Velasco Pérez.  [Dabigatran versus warfarin in patients with mechanical heart valves]. , 2014, Revista clinica espanola.

[487]  R. Kalil,et al.  Randomized study of surgery for patients with permanent atrial fibrillation as a result of mitral valve disease. , 2004, The Annals of thoracic surgery.

[488]  C. Gieger,et al.  A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke , 2009, Nature Genetics.

[489]  S. Jensen,et al.  A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). , 2007, European heart journal.

[490]  W. Manning,et al.  Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. , 2001, The American journal of medicine.

[491]  J. Cairns,et al.  nonvalvular atrial fibrillation , 2007 .

[492]  P. Danias,et al.  Risk for Clinical Thromboembolism Associated with Conversion to Sinus Rhythm in Patients with Atrial Fibrillation Lasting Less Than 48 Hours , 1997, Annals of Internal Medicine.

[493]  J. Shepherd,et al.  Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. , 2008, Health technology assessment.

[494]  B. Psaty,et al.  Newly detected atrial fibrillation and compliance with antithrombotic guidelines. , 2007, Archives of internal medicine.

[495]  D. Ferrante,et al.  Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. , 2013, Journal of the American College of Cardiology.

[496]  H. Nakagawa,et al.  The Intrinsic Autonomic Nervous System in Atrial Fibrillation: A Review , 2012, ISRN cardiology.

[497]  R. Asinger,et al.  Warfarin in atrial fibrillation patients with moderate chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[498]  M. Noble,et al.  Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. , 1998, Circulation.

[499]  M. Aguilar,et al.  Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No History of Stroke or Transient Ischemic Attacks , 2008 .

[500]  Silvia G Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.

[501]  P. Probst,et al.  Inefficacy of "therapeutic" serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. , 1975, The American journal of cardiology.

[502]  V. Hasselblad,et al.  Pulmonary Vein Isolation for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized, Controlled Trials , 2009, Circulation. Arrhythmia and electrophysiology.

[503]  W. Winkelmayer,et al.  Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[504]  J. Brugada,et al.  Atrial Fibrillation Catheter Ablation Versus Surgical Ablation Treatment (FAST): A 2-Center Randomized Clinical Trial , 2012, Circulation.

[505]  P. Coumel,et al.  Ventricular fibrillation in the Wolff-Parkinson-White syndrome. , 1991, European heart journal.

[506]  A. Waldo.  Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2006 .

[507]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[508]  P. Vestergaard,et al.  Alcohol and risk of atrial fibrillation or flutter: a cohort study. , 2004, Archives of internal medicine.

[509]  C. Gieger,et al.  Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke , 2008, Annals of neurology.

[510]  K. Ylitalo,et al.  Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[511]  Vadim V Fedorov,et al.  Anatomy and Electrophysiology of the Human AV Node , 2010, Pacing and clinical electrophysiology : PACE.

[512]  D. Levy,et al.  Obesity and the risk of new-onset atrial fibrillation. , 2004, JAMA.

[513]  Marlene R. Miller,et al.  The evidence regarding the drugs used for ventricular rate control. , 2000, The Journal of family practice.

[514]  R. Charnigo,et al.  Increased mortality among patients taking digoxin--analysis from the AFFIRM study. , 2013, European heart journal.

[515]  M. Mansour,et al.  Spatially Distributed Dominant Excitation Frequencies Reveal Hidden Organization in Atrial Fibrillation in the Langendorff‐Perfused Sheep Heart , 2000, Journal of cardiovascular electrophysiology.

[516]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[517]  Arterial embolism in thyrotoxicosis with atrial fibrillation. , 1981, Archives of internal medicine.

[518]  A. Amin,et al.  A pharmacologic overview of current and emerging anticoagulants. , 2005, Cleveland Clinic journal of medicine.

[519]  G. Wells,et al.  Approach to the Catheter Ablation Technique of Paroxysmal and Persistent Atrial Fibrillation: A Meta‐Analysis of the Randomized Controlled Trials , 2011, Journal of cardiovascular electrophysiology.

[520]  G. Feld,et al.  Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. , 1994, Circulation.

[521]  J. Kalman,et al.  Pulmonary Vein Antral Isolation for Paroxysmal Atrial Fibrillation: Results from Long‐Term Follow‐Up , 2010, Journal of cardiovascular electrophysiology.

[522]  N. Cook,et al.  Alcohol consumption and risk of incident atrial fibrillation in women. , 2008, JAMA.

[523]  John Spertus,et al.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.

[524]  M. Sakurai,et al.  Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting. , 2009, The Thoracic and cardiovascular surgeon.

[525]  R. Pistelli,et al.  Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. , 1995, The American journal of medicine.

[526]  S. Yusuf,et al.  Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.

[527]  Mark A. Wood,et al.  Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .

[528]  L. Jordaens,et al.  Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. , 1997, European heart journal.

[529]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[530]  Antonio De Simone,et al.  Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). , 2006, European heart journal.

[531]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[532]  D. Wyse,et al.  Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. , 2005, JAMA.

[533]  E. Mazzaferri.  Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults , 2007 .

[534]  L. Rydén,et al.  Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. , 1990, Journal of the American College of Cardiology.

[535]  M. Santini,et al.  Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. , 1996, Journal of the American College of Cardiology.

[536]  B. Reichart,et al.  Surgical treatment of permanent atrial fibrillation using microwave energy ablation: a prospective randomized clinical trial. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[537]  V. Somers,et al.  Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[538]  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2002 .

[539]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[540]  G. Breithardt,et al.  Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial , 2012 .

[541]  J. Healey,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. , 2014, JAMA.

[542]  P. Genton,et al.  Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism , 1984, Clinical pharmacology and therapeutics.

[543]  Adrian V. Hernández,et al.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.

[544]  A. Mills,et al.  Is discharge to home after emergency department cardioversion safe for the treatment of recent-onset atrial fibrillation? , 2011, Annals of emergency medicine.

[545]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.

[546]  Anne B Curtis,et al.  Biventricular pacing for atrioventricular block and systolic dysfunction. , 2013, The New England journal of medicine.

[547]  F. Sacher,et al.  Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study , 2008, Circulation.

[548]  李永军,et al.  Atrial Fibrillation , 1999 .

[549]  D M Mirvis,et al.  A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. , 1991, Journal of the American College of Cardiology.

[550]  N Waugh,et al.  Systematic review of the clinical effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease. , 2008, Health technology assessment.

[551]  D. Shah.  ECG manifestations of left atrial flutter , 2009, Current opinion in cardiology.

[552]  Dhanunjaya R. Lakkireddy,et al.  Periprocedural Stroke and Management of Major Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The Impact of Periprocedural Therapeutic International Normalized Ratio , 2010, Circulation.

[553]  S. Wessler,et al.  A Guide to Anticoagulant Therapy , 1961, Circulation.

[554]  N. Coplan,et al.  Embolic risk in atrial fibrillation that arises from hyperthyroidism: review of the medical literature. , 2011, Texas Heart Institute journal.

[555]  Muzahir Tayebjee,et al.  Characterization of Fractionated Atrial Electrograms Critical for Maintenance of Atrial Fibrillation: A Randomized, Controlled Trial of Ablation Strategies (The CFAE AF Trial) , 2011, Circulation. Arrhythmia and electrophysiology.

[556]  C. Lau,et al.  Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. , 2009, Heart rhythm.

[557]  L. Cohn,et al.  Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. , 1996, Circulation.

[558]  Michel Haïssaguerre,et al.  Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. , 2011, Journal of the American College of Cardiology.

[559]  M. Frenneaux,et al.  Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[560]  L. Køber,et al.  The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. , 1999, European heart journal.

[561]  B. Gersh,et al.  Long-Term Survival after Ablation of the Atrioventricular Node and Implantation of a Permanent Pacemaker in Patients with Atrial Fibrillation , 2001 .

[562]  M. Gold,et al.  Meta-Analysis of Bleeding Complications Associated With Cardiac Rhythm Device Implantation , 2012, Circulation. Arrhythmia and electrophysiology.

[563]  Douglas L Packer,et al.  Familial atrial fibrillation is a genetically heterogeneous disorder. , 2003, Journal of the American College of Cardiology.

[564]  Simon Stewart,et al.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. , 2002, The American journal of medicine.

[565]  Nancy R. Cook,et al.  Novel genetic markers improve measures of atrial fibrillation risk prediction , 2013, European heart journal.

[566]  Leif Hove-Madsen,et al.  Atrial Fibrillation Is Associated With Increased Spontaneous Calcium Release From the Sarcoplasmic Reticulum in Human Atrial Myocytes , 2004, Circulation.

[567]  S. Lotfipour,et al.  Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation , 2010, Internal and emergency medicine.

[568]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[569]  Wouter-Jan Rappel,et al.  Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. , 2012, Journal of the American College of Cardiology.

[570]  R. Krittayaphong,et al.  A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. , 2003, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[571]  K. Ellenbogen,et al.  Efficacy of ibutilide for termination of atrial fibrillation and flutter. , 1996, The American journal of cardiology.

[572]  G. Norman,et al.  Randomized controlled trials. , 2004, AJR. American journal of roentgenology.

[573]  G. Guyatt,et al.  Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. , 2003, Archives of internal medicine.

[574]  Janusz Wnek,et al.  2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults , 2013, Circulation.

[575]  J. Cleland,et al.  Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. , 2013, European heart journal.

[576]  G. Klein,et al.  Risk of Sudden Arrhythmic Death in the Wolff‐Parkinson‐White Syndrome: Current Perspectives , 1994, Pacing and clinical electrophysiology : PACE.

[577]  G. Breithardt,et al.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.

[578]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[579]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[580]  R. Califf,et al.  Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.

[581]  M. Brignole,et al.  Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. , 2011, European heart journal.

[582]  Hung-Fat Tse,et al.  Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation* , 2009, Critical care medicine.

[583]  David Keane,et al.  2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[584]  Judith S. Hochman,et al.  2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction , 2011 .

[585]  M. Hardy,et al.  Multiplanar phalangeal and metatarsal osteotomies for hallux rigidus. , 2011, Clinics in podiatric medicine and surgery.

[586]  F. Marchlinski,et al.  Time to recurrence of atrial fibrillation influences outcome following catheter ablation. , 2013, Heart rhythm.